Triple negative breast cancer

60 trials 17 recruiting MedDRA PT
60 Registered trials
17 Recruiting
41 Unique sponsors
48 Unique IMPs
37 Commercial trials
Drug classes (ATC)
— ATC code not specified 32
L Oncology (ATC L) 25
N Neurology/Psychiatry (ATC N) 1
A Gastroenterology (ATC A) 2
C Cardiology (ATC C) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 10 substances
Kinase inhibitor 6 substances
Antibody-drug conjugate (ADC) 4 substances
PARP inhibitor 3 substances
Monoclonal antibody (immune) 3 substances
Monoclonal antibody (tumor, humanized) 3 substances
Checkpoint inhibitor (PD-L1) 2 substances
Taxane 2 substances
Antimetabolite 2 substances
Monoclonal antibody 2 substances
Platinum compound 2 substances
Checkpoint inhibitor (PD-1) 1 substance
RAF/BRAF inhibitor 1 substance
BCL-2 inhibitor 1 substance
CDK inhibitor 1 substance
Alkylating agent 1 substance
Anthracycline 1 substance
Monoclonal antibody (human) 1 substance
Monoclonal antibody (angiogenesis) 1 substance
Statin 1 substance
Phase III: 13 Phase II: 21 Phase I/II: 6 Phase I: 15 Phase I (Other): 3 Phase I (First in Human): 3

Filter these 60 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 60 trials

Phase III

13 trials
  • AstraZeneca AB Commercial
    DATOPOTAMAB DERUXTECAN; DURVALUMAB
    2023-505552-22-00 8 countries 2023 n=269
    Ended
  • AstraZeneca AB Commercial
    DATOPOTAMAB DERUXTECAN; DURVALUMAB; OLAPARIB
    2023-505928-59-00 9 countries 2024 n=501
    Ended
  • AstraZeneca AB Commercial
    DATOPOTAMAB DERUXTECAN
    2023-509260-25-00 7 countries 2022 n=177
    Ended
  • F. Hoffmann-La Roche AG Commercial
    ALECTINIB; ALECTINIB HYDROCHLORIDE; ATEZOLIZUMAB; CABOZANTINIB; COBIMETINIB; NIRAPARIB; PACLITAXEL; PEMETREXED; SUNITINIB; VEMURAFENIB; VENETOCLAX
    2023-506184-34-00 11 countries 2019 n=104 Orphan
    Ended
  • Gilead Sciences Inc. Commercial
    CAPECITABINE; PEMBROLIZUMAB; SACITUZUMAB GOVITECAN
    2024-512279-10-00 6 countries 2024 n=758
    Recruiting
  • Glaxosmithkline Research & Development Limited Commercial
    NIRAPARIB TOSILATE MONOHYDRATE
    2023-504454-35-00 4 countries 2021 n=143
    Ended
  • Merck Sharp & Dohme LLC Commercial
    PEMBROLIZUMAB
    2022-501382-49-00 8 countries 2017 n=439
    Ended
  • Obi Pharma Inc. Commercial
    OBI-821
    2023-508755-39-00 1 country 2022 n=36
    Ended
  • WSG Westdeutsche Studiengruppe GmbH Commercial
    PEMBROLIZUMAB; SACITUZUMAB GOVITECAN
    2024-516734-35-00 1 country n=690
    Pending
  • GBG Forschungs GmbH Academic
    CAPECITABINE; CARBOPLATIN; CISPLATIN; SACITUZUMAB GOVITECAN
    2023-510390-33-00 6 countries 2020 n=1,386
    Ended
  • Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting Academic
    CAPECITABINE; OLAPARIB; PEMBROLIZUMAB; TEGAFUR, GIMERACIL, OTERACIL
    2025-524229-41-00 1 country n=1,000
    Pending
  • Unicancer Academic
    IMP not specified
    2024-513707-14-00 1 country 2022 n=646
    Ended
  • Universita Degli Studi Di Padova Academic
    AVELUMAB
    2024-514515-10-00 1 country 2016 n=450
    Ended

Phase II

21 trials
  • AstraZeneca AB Commercial
    CERALASERTIB; OLAPARIB
    2024-514205-60-00 3 countries 2018 n=3
    Ended
  • Bicycletx Limited Commercial
    ZELENECTIDE PEVEDOTIN
    2024-517868-33-00 4 countries 2025 n=30
    Ended
  • F. Hoffmann-La Roche AG Commercial
    IMP not specified
    2022-502457-34-00 8 countries 2024 n=71
    Ended
  • Medica Scientia Innovation Research S.L. Commercial
    DOMVANALIMAB; SACITUZUMAB GOVITECAN; ZIMBERELIMAB
    2025-521489-80-00 1 country n=25
    Ended
  • Merck Sharp & Dohme LLC Commercial
    PATRITUMAB DERUXTECAN; PEMBROLIZUMAB
    2024-514376-40-00 1 country 2025 n=10
    Recruiting
  • WSG Westdeutsche Studiengruppe GmbH Commercial
    PEMBROLIZUMAB; SACITUZUMAB GOVITECAN
    2023-508787-29-00 1 country 2024 n=348
    Recruiting
  • Champalimaud Clinical Centre Academic
    PEMBROLIZUMAB
    2023-507008-30-00 1 country 2024 n=20
    Recruiting
  • Fondazione IRCCS Istituto Nazionale Dei Tumori Academic
    METFORMIN HYDROCHLORIDE
    2023-508920-37-00 1 country 2020 n=32
    Ended
  • Institut Curie Academic
    (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHYLCARBAMOYL)-QUINOLIN-6-YL)(METHYL)AMINO)-PROPYL)PIPERAZIN-1-YL)-2-OXOETHYL)-68GA-[1,4,7,10]-TETRAAZACYCLODODECANE-1,4,7-TRIYL)TRIACETATE; ATEZOLIZUMAB; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN HYDROCHLORIDE; PACLITAXEL ALBUMIN-BOUND; TIRAGOLUMAB
    2022-501561-51-00 1 country 2024 n=160
    Ended
  • Institut Curie Academic
    (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHYLCARBAMOYL)-QUINOLIN-6-YL)(METHYL)AMINO)-PROPYL)PIPERAZIN-1-YL)-2-OXOETHYL)-68GA-[1,4,7,10]-TETRAAZACYCLODODECANE-1,4,7-TRIYL)TRIACETATE
    2022-501562-22-00 1 country n=450
    Not authorised
  • Institut Curie Academic
    (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHYLCARBAMOYL)-QUINOLIN-6-YL)(METHYL)AMINO)-PROPYL)PIPERAZIN-1-YL)-2-OXOETHYL)-68GA-[1,4,7,10]-TETRAAZACYCLODODECANE-1,4,7-TRIYL)TRIACETATE
    2022-501562-22-01 1 country 2026 n=450
    Recruiting
  • Institut Curie Academic
    ATEZOLIZUMAB; RP1
    2022-502311-12-00 1 country 2024 n=51
    Ended
  • Institut Gustave Roussy Academic
    ATEZOLIZUMAB; BEVACIZUMAB; PERTUZUMAB; TRASTUZUMAB
    2024-512826-26-00 1 country 2022 n=185
    Ended
  • Istituto Europeo Di Oncologia S.r.l. Academic
    ATEZOLIZUMAB
    2024-514031-20-00 1 country 2025 n=45
    Recruiting
  • Karolinska University Hospital Academic
    ATEZOLIZUMAB; PACLITAXEL ALBUMIN-BOUND
    2022-500808-21-00 1 country 2023 n=64
    Ended
  • Unicancer Academic
    PEMBROLIZUMAB
    2023-504620-26-00 2 countries 2024 n=364
    Recruiting
  • Unicancer Academic
    IMP not specified
    2023-505291-30-01 1 country 2025 n=220
    Recruiting
  • Universita Degli Studi Di Padova Academic
    ATORVASTATIN
    2024-518500-47-00 1 country 2026 n=90
    Recruiting
  • Vaestra Goetalandsregionen Academic
    IMP not specified
    2024-511141-19-00 1 country 2022 n=40
    Recruiting
  • Verein Zur Praevention Und Therapie Boesartiger Erkrankungen Austrian Breast And Colorectal Cancer Study Group Academic
    OLAPARIB
    2024-512821-10-00 1 country 2019 n=90
    Ended
  • Fondazione IRCCS Istituto Nazionale Dei Tumori Academic
    METFORMIN HYDROCHLORIDE
    2023-508920-37-00 1 country 2020 n=32
    Ended

Phase I/II

6 trials
  • AstraZeneca AB Commercial
    CAPIVASERTIB; DATOPOTAMAB DERUXTECAN; DURVALUMAB; OLECLUMAB; TRASTUZUMAB DERUXTECAN
    2024-511646-40-00 1 country 2019 n=61
    Ended
  • Cantargia AB Commercial
    NADUNOLIMAB
    2024-512052-38-00 1 country 2021 n=117
    Ended
  • Cyclacel Limited Commercial
    FADRACICLIB
    2024-516289-12-00 1 country 2022 n=30
    Ended
  • Eisai Limited Commercial
    FARLETUZUMAB ECTERIBULIN; LENVATINIB
    2023-506868-14-00 2 countries 2023 n=90
    Ended
  • NEC Bio Therapeutics GmbH Commercial
    NECVAX-NEO1; PACLITAXEL ALBUMIN-BOUND
    2024-512520-11-00 1 country 2024 n=28
    Recruiting
  • Institut Jules Bordet Academic
    DURVALUMAB; OLECLUMAB
    2024-511850-34-00 2 countries 2019 n=209
    Ended

Phase I

15 trials
  • Beigene Ltd. Commercial
    IMP not specified
    2023-503996-38-00 1 country 2025 n=60
    Ended
  • Beigene Ltd. Commercial
    IMP not specified
    2023-505322-34-00 1 country 2024 n=45
    Ended
  • BeOne Medicines AG Commercial
    IMP not specified
    2025-523165-19-00 1 country 2026 n=15
    Recruiting
  • Fusion Pharmaceuticals Inc. Commercial
    IMP not specified
    2025-521235-37-00 1 country n=45
    Ended
  • Merck Healthcare KGaA Commercial
    IMP not specified
    2025-523232-39-00 1 country n=14
    Pending
  • Novartis Pharma AG Commercial
    IMP not specified
    2022-502381-25-01 4 countries 2024 n=97
    Ended
  • Novartis Pharma AG Commercial
    IMP not specified
    2023-510356-23-00 6 countries 2025 n=76
    Recruiting
  • Novartis Pharma AG Commercial
    IMP not specified
    2024-513281-19-00 2 countries 2024 n=32
    Ended
  • Novartis Pharma AG Commercial
    IMP not specified
    2025-521702-18-00 5 countries 2026 n=62
    Recruiting
  • Nykode Therapeutics ASA Commercial
    IMP not specified
    2023-509996-18-00 2 countries 2022 n=40
    Ended
  • Seagen Inc. Commercial
    IMP not specified
    2023-503389-22-00 4 countries 2022 n=147
    Ended
  • Seagen Inc. Commercial
    IMP not specified
    2023-506604-18-00 6 countries 2024 n=177
    Recruiting
  • Valo Therapeutics Oy Commercial
    IMP not specified
    2024-517580-23-00 2 countries 2023 n=23
    Ended
  • Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer Academic
    IMP not specified
    2024-511915-21-01 1 country 2025 n=20
    Recruiting
  • Incyte Corp. Academic
    IMP not specified
    2023-504400-29-00 1 country 2022 n=9
    Ended

Phase I (Other)

3 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    IMP not specified
    2023-506227-29-00 2 countries 2024 n=60
    Recruiting
  • Exelixis Inc. Commercial
    IMP not specified
    2024-516477-73-00 2 countries 2018 n=320
    Ended
  • Pfizer Inc. Commercial
    IMP not specified
    2024-518696-65-00 1 country 2025 n=9
    Ended

Phase I (First in Human)

3 trials
  • Salubris Biotherapeutics Inc. Commercial
    JK08; LENVATINIB; PEMBROLIZUMAB
    2024-511750-53-00 2 countries 2022 n=130
    Ended
  • Celica d.o.o. Academic
    IMP not specified
    2023-506019-16-01 1 country n=50
    Not authorised
  • Celica d.o.o. Academic
    IMP not specified
    2023-506019-16-03 1 country n=82
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
AstraZeneca AB Commercial 5 Phase II, Phase III, Phase I/II 0
Novartis Pharma AG Commercial 4 Phase I 2
Institut Curie Academic 4 Phase II 1
Unicancer Academic 3 Phase II, Phase III 2
Beigene Ltd. Commercial 2 Phase I 0
Seagen Inc. Commercial 2 Phase I 1
F. Hoffmann-La Roche AG Commercial 2 Phase II, Phase III 0
Merck Sharp & Dohme LLC Commercial 2 Phase II, Phase III 1
WSG Westdeutsche Studiengruppe GmbH Commercial 2 Phase II, Phase III 1
Fondazione IRCCS Istituto Nazionale Dei Tumori Academic 2 Phase II 0
Universita Degli Studi Di Padova Academic 2 Phase II, Phase III 1
Celica d.o.o. Academic 2 Phase I (First in Human) 0
BeOne Medicines AG Commercial 1 Phase I 1
Fusion Pharmaceuticals Inc. Commercial 1 Phase I 0
Merck Healthcare KGaA Commercial 1 Phase I 0
Nykode Therapeutics ASA Commercial 1 Phase I 0
Valo Therapeutics Oy Commercial 1 Phase I 0
AbbVie Deutschland GmbH & Co. KG Commercial 1 Phase I (Other) 1
Exelixis Inc. Commercial 1 Phase I (Other) 0
Pfizer Inc. Commercial 1 Phase I (Other) 0
New trials by year
2019
4
2020
3
2021
2
2022
10
2023
4
2024
14
2025
8
2026
4
← All indication landscapes